Biotech To Be An Increasing Force In M&A

In a move that further highlights the its focus on bio-tech, Swiss pharmaceutical giant Roche Holding confirmed on November 25 that it had agreed to acquire US firm Memory Pharmaceuticals for around US$50mn. The deal will see Roche start a tender offer for all outstanding Memory common stock at a price of US$0.61 per share, a 319% premium to the stocks closing price on November 24. Memory focuses on the development of innovative drugs for the treatment of debilitating central nervous system (CNS) such as Alzheimer's, and certain psychiatric disorders such as schizophrenia, bipolar disorder and depression. Indeed, it already

To read the full article, please choose one of the following options: